Pfizer Oncology Head Charles Baum: An Interview With “The Pink Sheet” DAILY (Part 1 Of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer VP and Oncology Therapeutic Head Charles Baum talks to “The Pink Sheet” DAILY in an exclusive interview about the pharma giant’s increasing research emphasis in cancer drugs, and about pipeline developments, including axitinib in pancreatic cancer and a CTLA4 inhibitor, tremelimumab, for melanoma.
You may also be interested in...
Medarex/Bristol Plan To File Ipilimumab For Metastatic Melanoma Despite Phase II Failure
Totality of the data, clear dose response and limited treatment options in this patient population justify regulatory approval, firms maintain.
Medarex/Bristol Plan To File Ipilimumab For Metastatic Melanoma Despite Phase II Failure
Totality of the data, clear dose response and limited treatment options in this patient population justify regulatory approval, firms maintain.
Avastin Added To Tarceva/Gemcitabine Fails To Prolong Survival In Phase III Pancreatic Cancer Trial
Roche-sponsored trial did not meet the primary endpoint of overall survival, but did show some clinical benefits.